Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of benzenesulfonamides, characterized by a propanoic acid backbone substituted with a 3-(aminomethyl)phenyl group and a phosphoryl group further modified with an (R)-(hydroxy)-(1R)-2-methyl-1-(phenylsulfonylamino)propyl moiety. It has been catalogued as DrugBank DB06921 and is considered experimental, with no approved indications or clinical trial activity reported. Its mechanism of action, biological targets, and therapeutic potential are not described in public sources. The compound's structure suggests it may have been investigated as an enzyme inhibitor or for other research purposes[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-[3-(aminomethyl)phenyl]-3-[(R)-hydroxy{(1R)-2-methyl-1-[(phenylsulfonyl)amino]propyl}phosphoryl]propanoic acid.